Dynamic Changes in Adiponectin and Resistin Drive Remission of Cardiometabolic Risk Biomarkers in Individuals with Obesity Following Bariatric Surgery

Figures

• 

  Figure 1. Correlation between serum adiponectin levels variation and cardiometabolic risk biomarker variation in patients preoperatively and six months after bariatric surgery (n = 24). (A) Glycemia; (B) Insulin; (C) resistin; (D) Total cholesterol; (E) HDL cholesterol; (F) LDL cholesterol; (G) Triglycerides; (H) CRP; (I) TNF-α; (J) PAI-1. r: Pearson’s correlation coefficient or Spearman’s correlation coefficient when normality was rejected in the Shapiro–Wilk test; p < 0.05. (Δ) Difference between the levels of biological analytes in patients’ serum six months after surgery and the preoperative concentration; (CRP) C-Reactive Protein; (TNF-α) Tumor necrosis factor alpha; (LDL) Low-density lipoprotein; (HDL) High-density lipoprotein; PAI-1: Plasminogen activator inhibitor-1.

• 

  Figure 2. Correlation between serum resistin levels variation and cardiometabolic risk biomarker variation in patients preoperatively and six months after bariatric surgery (n = 24). (A) Glycemia; (B) Insulin; (C) CRP; (D) TNF-α; (E) PAI-1; (F) Triglycerides; (G) Total cholesterol; (H) HDL cholesterol; (I) LDL cholesterol. r: Pearson’s correlation coefficient or Spearman’s correlation coefficient when normality was rejected in the Shapiro–Wilk test; p < 0.05. (Δ) Difference between the concentration of biological analytes in patients’ serum six months after surgery and the preoperative concentration; (CRP) C-Reactive Protein; (TNF-α) Tumor necrosis factor alpha; (LDL) Low-density lipoprotein; (HDL) High-density lipoprotein; PAI-1: Plasminogen activator inhibitor-1.

• 

  Figure 3. Sample selection process.